Literature DB >> 19644599

[Patients with oral anticoagulation--bridging anticoagulation in the perioperative phase].

J Koscielny1, S Ziemer, C von Heymann.   

Abstract

Oral anticoagulation with a vitamin K-antagonist requires special consideration when surgery or interventional procedures are planned. This is mainly due to the half life of vitamin K-antagonists and to the need for safe and effective anticoagulation prior to and during surgery as well as in the postoperative period. So far, the continuous infusion of unfractionated heparin (UFH) has been the medication of choice to "bridge" patients to surgery. The use of low molecular weight heparins (LMWH) has been prospectively investigated in this setting and represents a safe alternative. The advantages of LMWH are the better dose-response relationship and reduced need for monitoring. This facilitates the bridging procedure to be started out of hospital, which may reduce hospital stay and associated costs. Furthermore, the so-called bridging of patients with oral anticoagulation prior to and during surgery reduces bleeding complications and maintains a safe anticoagulation for patients at risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19644599

Source DB:  PubMed          Journal:  Hamostaseologie        ISSN: 0720-9355            Impact factor:   1.778


  3 in total

Review 1.  [Current aspects of anesthetic management in urological patients].

Authors:  O Groll; J Peters
Journal:  Urologe A       Date:  2010-09       Impact factor: 0.639

2.  Persistence with VKA treatment in newly treated atrial fibrillation patients: an analysis based on a large sample of 38,076 German patients.

Authors:  Thomas Wilke; Antje Groth; Andreas Fuchs; Matthias Pfannkuche; Ulf Maywald
Journal:  Eur J Clin Pharmacol       Date:  2017-08-05       Impact factor: 2.953

3.  [Perioperative conversion of oral anticoagulants to heparin (bridging) in ophthalmic medicine].

Authors:  N Feltgen; A Pielen; L-O Hattenbach; U Geisen; J Heinz
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.